Publication | Closed Access

Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study

Lymphoid NeoplasiaFirst-line TherapySurgical OncologyPhase Ii TrialMedicinePathologyImmune Checkpoint InhibitorCancer TreatmentImmunotherapyOncologyRadiation OncologyCvp Combination Chemotherapy